Literature DB >> 20630757

Clinical and genetic characterization of manifesting carriers of DMD mutations.

Payam Soltanzadeh1, Michael J Friez, Diane Dunn, Andrew von Niederhausern, Olga L Gurvich, Kathryn J Swoboda, Jacinda B Sampson, Alan Pestronk, Anne M Connolly, Julaine M Florence, Richard S Finkel, Carsten G Bönnemann, Livija Medne, Jerry R Mendell, Katherine D Mathews, Brenda L Wong, Michael D Sussman, Jonathan Zonana, Karen Kovak, Sidney M Gospe, Eduard Gappmaier, Laura E Taylor, Michael T Howard, Robert B Weiss, Kevin M Flanigan.   

Abstract

Manifesting carriers of DMD gene mutations may present diagnostic challenges, particularly in the absence of a family history of dystrophinopathy. We review the clinical and genetic features in 15 manifesting carriers identified among 860 subjects within the United Dystrophinopathy Project, a large clinical dystrophinopathy cohort whose members undergo comprehensive DMD mutation analysis. We defined manifesting carriers as females with significant weakness, excluding those with only myalgias/cramps. DNA extracted from peripheral blood was used to study X-chromosome inactivation patterns. Among these manifesting carriers, age at symptom onset ranged from 2 to 47 years. Seven had no family history and eight had male relatives with Duchenne muscular dystrophy (DMD). Clinical severity among the manifesting carriers varied from a DMD-like progression to a very mild Becker muscular dystrophy-like phenotype. Eight had exonic deletions or duplications and six had point mutations. One patient had two mutations (an exonic deletion and a splice site mutation), consistent with a heterozygous compound state. The X-chromosome inactivation pattern was skewed toward non-random in four out of seven informative deletions or duplications but was random in all cases with nonsense mutations. We present the results of DMD mutation analysis in this manifesting carrier cohort, including the first example of a presumably compound heterozygous DMD mutation. Our results demonstrate that improved molecular diagnostic methods facilitate the identification of DMD mutations in manifesting carriers, and confirm the heterogeneity of mutational mechanisms as well as the wide spectrum of phenotypes. 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20630757      PMCID: PMC2944769          DOI: 10.1016/j.nmd.2010.05.010

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  27 in total

1.  Detection of point mutation in dystrophin gene reveals somatic and germline mosaicism in the mother of a patient with Duchenne muscular dystrophy.

Authors:  Anthonie J van Essen; Inge M Mulder; Pieter van der Vlies; Annemarie H van der Hout; Charles H C M Buys; Robert M W Hofstra; Johan T den Dunnen
Journal:  Am J Med Genet A       Date:  2003-04-30       Impact factor: 2.802

2.  Mosaic expression of dystrophin in symptomatic carriers of Duchenne's muscular dystrophy.

Authors:  K Arahata; T Ishihara; K Kamakura; T Tsukahara; S Ishiura; C Baba; T Matsumoto; I Nonaka; H Sugita
Journal:  N Engl J Med       Date:  1989-01-19       Impact factor: 91.245

3.  The manifesting carrier in Duchenne muscular dystrophy.

Authors:  H Moser; A E Emery
Journal:  Clin Genet       Date:  1974       Impact factor: 4.438

4.  Signs and symptoms of Duchenne muscular dystrophy and Becker muscular dystrophy among carriers in The Netherlands: a cohort study.

Authors:  E M Hoogerwaard; E Bakker; P F Ippel; J C Oosterwijk; D F Majoor-Krakauer; N J Leschot; A J Van Essen; H G Brunner; P A van der Wouw; A A Wilde; M de Visser
Journal:  Lancet       Date:  1999-06-19       Impact factor: 79.321

5.  Cardiac involvement in carriers of Duchenne and Becker muscular dystrophy.

Authors:  E M Hoogerwaard; P A van der Wouw; A A Wilde; E Bakker; P F Ippel; J C Oosterwijk; D F Majoor-Krakauer; A J van Essen; N J Leschot; M de Visser
Journal:  Neuromuscul Disord       Date:  1999-07       Impact factor: 4.296

6.  Comparison of X-chromosome inactivation patterns in multiple tissues from human females.

Authors:  D C Bittel; M F Theodoro; N Kibiryeva; W Fischer; Z Talebizadeh; M G Butler
Journal:  J Med Genet       Date:  2007-12-21       Impact factor: 6.318

Review 7.  A carrier of Duchenne muscular dystrophy with dilated cardiomyopathy but no skeletal muscle symptom.

Authors:  H Kinoshita; Y Goto; M Ishikawa; T Uemura; K Matsumoto; Y K Hayashi; K Arahata; I Nonaka
Journal:  Brain Dev       Date:  1995 May-Jun       Impact factor: 1.961

8.  A survey of manifesting carriers of Duchenne and Becker muscular dystrophy in Wales.

Authors:  A Norman; P Harper
Journal:  Clin Genet       Date:  1989-07       Impact factor: 4.438

9.  Rapid direct sequence analysis of the dystrophin gene.

Authors:  Kevin M Flanigan; Andrew von Niederhausern; Diane M Dunn; Jonathan Alder; Jerry R Mendell; Robert B Weiss
Journal:  Am J Hum Genet       Date:  2003-03-11       Impact factor: 11.025

10.  Skewed X-chromosome inactivation is a common feature of X-linked mental retardation disorders.

Authors:  Robert M Plenge; Roger A Stevenson; Herbert A Lubs; Charles E Schwartz; Huntington F Willard
Journal:  Am J Hum Genet       Date:  2002-05-30       Impact factor: 11.025

View more
  42 in total

Review 1.  The Role of Genetics in Peripartum Cardiomyopathy.

Authors:  Yi Zhen Joan Lee; Daniel P Judge
Journal:  J Cardiovasc Transl Res       Date:  2017-08-03       Impact factor: 4.132

2.  Dystrophin hydrophobic regions in the pathogenesis of Duchenne and Becker muscular dystrophies.

Authors:  Yingyin Liang; Songlin Chen; Jianzong Zhu; Xiangxue Zhou; Chen Yang; Lu Yao; Cheng Zhang
Journal:  Bosn J Basic Med Sci       Date:  2015-05-20       Impact factor: 3.363

3.  Gender differences in contractile and passive properties of mdx extensor digitorum longus muscle.

Authors:  Chady H Hakim; Dongsheng Duan
Journal:  Muscle Nerve       Date:  2012-02       Impact factor: 3.217

4.  Genetic and clinical specificity of 26 symptomatic carriers for dystrophinopathies at pediatric age.

Authors:  Sandra Mercier; Annick Toutain; Aurélie Toussaint; Martine Raynaud; Claire de Barace; Pascale Marcorelles; Laurent Pasquier; Martine Blayau; Caroline Espil; Philippe Parent; Hubert Journel; Leila Lazaro; Jon Andoni Urtizberea; Alexandre Moerman; Laurence Faivre; Bruno Eymard; Kim Maincent; Romain Gherardi; Denys Chaigne; Rabah Ben Yaou; France Leturcq; Jamel Chelly; Isabelle Desguerre
Journal:  Eur J Hum Genet       Date:  2013-01-09       Impact factor: 4.246

5.  Novel mosaic mutation in the dystrophin gene causing distal asymmetric muscle weakness of the upper limbs and dilated cardiomyopathy.

Authors:  Joana Ribeiro; Olinda Rebelo; Ana Fernández-Marmiesse; Luís Negrão
Journal:  Acta Myol       Date:  2018-06-01

6.  Clinical and Genetic Characterization of Female Dystrophinopathy.

Authors:  Seung Ha Lee; Jung Hwan Lee; Kyung A Lee; Young Chul Choi
Journal:  J Clin Neurol       Date:  2015-05-28       Impact factor: 3.077

7.  Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings.

Authors:  Kate Bushby; Edward Connor
Journal:  Clin Investig (Lond)       Date:  2011-09

Review 8.  Challenging the Current Recommendations for Carrier Testing in Children.

Authors:  Grace E VanNoy; Casie A Genetti; Amy L McGuire; Robert C Green; Alan H Beggs; Ingrid A Holm
Journal:  Pediatrics       Date:  2019-01       Impact factor: 7.124

Review 9.  Determining the role of skewed X-chromosome inactivation in developing muscle symptoms in carriers of Duchenne muscular dystrophy.

Authors:  Emanuela Viggiano; Manuela Ergoli; Esther Picillo; Luisa Politano
Journal:  Hum Genet       Date:  2016-04-21       Impact factor: 4.132

10.  Whole exome sequencing identifies three recessive FIG4 mutations in an apparently dominant pedigree with Charcot-Marie-Tooth disease.

Authors:  Manoj P Menezes; Leigh Waddell; Guy M Lenk; Simranpreet Kaur; Daniel G MacArthur; Miriam H Meisler; Nigel F Clarke
Journal:  Neuromuscul Disord       Date:  2014-05-04       Impact factor: 4.296

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.